S&P 500   3,571.69 (+0.40%)
DOW   29,540.50 (+0.95%)
QQQ   289.80 (-0.20%)
AAPL   114.18 (-2.69%)
MSFT   209.33 (-0.50%)
FB   268.45 (-0.46%)
GOOGL   1,722.68 (-0.79%)
AMZN   3,095.33 (-0.13%)
TSLA   522.44 (+6.71%)
NVDA   523.82 (+0.06%)
BABA   270.11 (-0.23%)
CGC   24.98 (+5.31%)
GE   10.14 (+3.89%)
MU   63.81 (+3.93%)
AMD   84.88 (+0.28%)
T   28.57 (+0.88%)
NIO   54.25 (+10.15%)
F   8.90 (+1.83%)
ACB   7.38 (+3.51%)
GILD   59.58 (-0.88%)
NFLX   480.00 (-1.69%)
BA   211.44 (+5.92%)
DIS   146.73 (+4.01%)
S&P 500   3,571.69 (+0.40%)
DOW   29,540.50 (+0.95%)
QQQ   289.80 (-0.20%)
AAPL   114.18 (-2.69%)
MSFT   209.33 (-0.50%)
FB   268.45 (-0.46%)
GOOGL   1,722.68 (-0.79%)
AMZN   3,095.33 (-0.13%)
TSLA   522.44 (+6.71%)
NVDA   523.82 (+0.06%)
BABA   270.11 (-0.23%)
CGC   24.98 (+5.31%)
GE   10.14 (+3.89%)
MU   63.81 (+3.93%)
AMD   84.88 (+0.28%)
T   28.57 (+0.88%)
NIO   54.25 (+10.15%)
F   8.90 (+1.83%)
ACB   7.38 (+3.51%)
GILD   59.58 (-0.88%)
NFLX   480.00 (-1.69%)
BA   211.44 (+5.92%)
DIS   146.73 (+4.01%)
S&P 500   3,571.69 (+0.40%)
DOW   29,540.50 (+0.95%)
QQQ   289.80 (-0.20%)
AAPL   114.18 (-2.69%)
MSFT   209.33 (-0.50%)
FB   268.45 (-0.46%)
GOOGL   1,722.68 (-0.79%)
AMZN   3,095.33 (-0.13%)
TSLA   522.44 (+6.71%)
NVDA   523.82 (+0.06%)
BABA   270.11 (-0.23%)
CGC   24.98 (+5.31%)
GE   10.14 (+3.89%)
MU   63.81 (+3.93%)
AMD   84.88 (+0.28%)
T   28.57 (+0.88%)
NIO   54.25 (+10.15%)
F   8.90 (+1.83%)
ACB   7.38 (+3.51%)
GILD   59.58 (-0.88%)
NFLX   480.00 (-1.69%)
BA   211.44 (+5.92%)
DIS   146.73 (+4.01%)
S&P 500   3,571.69 (+0.40%)
DOW   29,540.50 (+0.95%)
QQQ   289.80 (-0.20%)
AAPL   114.18 (-2.69%)
MSFT   209.33 (-0.50%)
FB   268.45 (-0.46%)
GOOGL   1,722.68 (-0.79%)
AMZN   3,095.33 (-0.13%)
TSLA   522.44 (+6.71%)
NVDA   523.82 (+0.06%)
BABA   270.11 (-0.23%)
CGC   24.98 (+5.31%)
GE   10.14 (+3.89%)
MU   63.81 (+3.93%)
AMD   84.88 (+0.28%)
T   28.57 (+0.88%)
NIO   54.25 (+10.15%)
F   8.90 (+1.83%)
ACB   7.38 (+3.51%)
GILD   59.58 (-0.88%)
NFLX   480.00 (-1.69%)
BA   211.44 (+5.92%)
DIS   146.73 (+4.01%)
Log in
NASDAQ:OPHT

IVERIC bio Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$5.80
+0.14 (+2.47 %)
(As of 11/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.52
Now: $5.80
$5.83
50-Day Range
$1.13
MA: $1.30
$1.39
52-Week Range
$1.02
Now: $5.80
$4.50
Volume615,399 shs
Average Volume159,109 shs
Market Capitalization$240.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
Read More
IVERIC bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPHT
CUSIPN/A
Phone(212) 845-8200
Employees35

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$209.98 million
Book Value$3.00 per share

Profitability

Net Income$63.09 million

Miscellaneous

Market Cap$240.24 million
Next Earnings DateN/A
OptionableOptionable

Receive OPHT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IVERIC bio (NASDAQ:OPHT) Frequently Asked Questions

What stocks does MarketBeat like better than IVERIC bio?

Wall Street analysts have given IVERIC bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IVERIC bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:OPHT) posted its quarterly earnings results on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.02.
View IVERIC bio's earnings history
.

Who are some of IVERIC bio's key competitors?

What other stocks do shareholders of IVERIC bio own?

Who are IVERIC bio's key executives?

IVERIC bio's management team includes the following people:
  • Glenn P. Sblendorio, President, Chief Executive Officer & Director
  • Keith Westby, Chief Operating Officer & Senior Vice President
  • David F. Carroll, Chief Financial Officer, Treasurer & SVP
  • Kourous A. Rezaei, Chief Medical Officer & Senior Vice President
  • Abraham Scaria, Chief Scientific Officer

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "OPHT."

What is IVERIC bio's stock price today?

One share of OPHT stock can currently be purchased for approximately $5.80.

How big of a company is IVERIC bio?

IVERIC bio has a market capitalization of $240.24 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $63.09 million in net income (profit) each year or ($1.67) on an earnings per share basis. IVERIC bio employs 35 workers across the globe.

What is IVERIC bio's official website?

The official website for IVERIC bio is www.ophthotech.com.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at (212) 845-8200 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.